Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pendahuluan: Dalam 2 dekade terakhir ini, berbagai penelitian epidemiologi menunjukkan adanya kecenderungan peningkatan angka insidens dan prevalensi diabetes mellitus (DM) tipe-2 di berbagai penjuru dunia. Selain itu, DM tipe 2 kini juga diketahui menjadi salah satu faktor risiko penyakit tuberkulosis (TB) paru. Penelitian ini bertujuan untuk mengetahui pengaruh jenis kelamin terhadap prevalensi TB paru pada pasien DM tipe 2. Metode: Dengan desain cross-sectional, pengambilan sampel dilakukan terhadap seluruh pasien DM tipe 2 yang menderita infeksi paru (TB dan bukan TB) di Rumah Sakit Cipto Mangunkusumo tahun 2010. Hasil: Hasil menunjukkan dari 125 pasien DM tipe 2 yang menderita TB paru, 82 berjenis kelamin laki-laki (67%) dan 43 berjenis kelamin perempuan (33%). Kesimpulan: Dapat disimpulkan bahwa jenis kelamin mempengaruhi prevalensi TB pada penderita DM tipe 2 secara bermakna.

---

Background: In the last 2 decades, many epidemiological studies showed increment tendency of incidence and prevalence of type 2 diabetes mellitus (DM) in many regions of the world. Besides, type 2 DM has also known as a risk factor for lung tuberculosis (TB). The study purpose is to find out the effect of gender to lung TB prevalence in type 2 DM patients.

Method: With cross-sectional design, sampling was taken from all type 2 DM patients with lung infection (TB and non-TB) in Cipto Mangunkusumo Hospital in year 2010.

Result: Result show that amongst 125 type 2 DM patients who had lung TB, 82 of them are males (66%) and the 43 are females (33%).

Conclusion: From this study, we can conclude that gender affect the TB lung prevalence in type 2 DM patients."

"Setidaknya 1 dari 200 pasien COVID-19 akan mengalami DVT, dan sekitar 20% kasus VTE berhubungan dengan COVID-19. Risikonya meningkat empat kali lipat pada pasien COVID-19. Munculnya berbagai faktor patofisiologis yang berkontribusi terhadap terjadinya DVT pada pasien COVID-19 menimbulkan pertanyaan menarik mengenai perbedaan dalam karakteristik luaran pasien DVT sebelum dan selama pandemi, serta variasi dalam perawatan dan hasil pasien. Desain penelitian yang digunakan adalah studi kohort retrospektif untuk melihat perbandingan karakteristik dan manajemen pasien DVT (Deep Vein Thrombosis) sebelum dan selama pandemi COVID-19. Didapatkan data 489 subyek yang diikutsertakan dalam penelitian ini dengan nilai rata-rata usianya adalah 50.72 ± 18.00. Berdasarkan waktu terkenanya DVT, dari 489 subyek tersebut, sebagian besar sampel yaitu sebanyak 344 orang (72.9%) merupakan pasien yang mengalami DVT selama pandemi COVID. Berdasarkan status mortalitas, terdapat 336 orang (71.8%) yang masih hidup setelah mengalami DVT. Berdasarkan keberadaan perdarahan hebat, sebagian besar subyek yaitu 402 orang (82.2%) tidak mengalami perdarahan hebat. Berdasarkan status rekurensi, terdapat 321 orang (65.7%) yang mengalami rekurensi yaitu kembali dirawat dengan diagnosa yang sama dalam 1 tahun pertama setelah pertama kali dirawat. Sebanyak 479 orang (97.9%) tidak mengalami emboli paru. Didapatkan nilai rata-rata durasi rawat inap selama 13.41 ± 9.89 hari. Berdasarkan hasil pemeriksaan D-Dimer, didapatkan nilai rata-rata 3008.21 ± 1494.59 ng/mL. Sedangkan hasil pemeriksaan fibrinogen, didapatkan nilai rata-rata 301.06 ± 58.63 mg/dL. Dalam melihat komparasi data DVT sebelum dan selama pandemic COVID-19, dari 4 variabel yang dilihat, hanya D-Dimer yang memiliki perbedaan yang signifikan berupa peningkatan nilai rata-rata apabila dibandingkan antara sebelum pandemic COVID (2052.34 ± 568.30 ng/mL) dan selama COVID (3363.89 ± 1573.79 ng/mL) dengan nilai p < 0.001. Hasil berbeda terjadi pada fibrinogen yang tidak memiliki perbedaan yang signifikan antara sebelum pandemic COVID (295.66 ± 57.28 mg/dL) dibandingkan dengan selama COVID (303.06 ± 59.08 mg/dL) dengan nilai p 0.223. Ditemukan bahwa pada pasien COVID-19 didapati nilai D-Dimer yang lebih tinggi (nilai p <0.001) serta fibrinogen yang lebih tinggi secara signifikan (p=0.032).

---

At least 1 in 200 COVID-19 patients will experience DVT, and approximately 20% of VTE cases are related to COVID-19. The risk increases fourfold in COVID-19 patients. The emergence of various pathophysiological factors that contribute to the occurrence of DVT in COVID-19 patients raises interesting questions regarding differences in the outcome characteristics of DVT patients before and during the pandemic, as well as variations in patient care and outcomes. The research design used was a retrospective cohort study to compare the characteristics and management of DVT (Deep Vein Thrombosis) patients before and during the COVID-19 pandemic. Data were obtained for 489 subjects who were included in this study with an average age value of 50.72 ± 18.00. Based on the time of DVT, of the 489 subjects, the majority of the sample, namely 344 people (72.9%) were patients who experienced DVT during the COVID pandemic. Based on mortality status, there were 336 people (71.8%) who were still alive after experiencing DVT. Based on the presence of severe bleeding, the majority of subjects, namely 402 people (82.2%) did not experience severe bleeding. Based on recurrence status, there were 321 people (65.7%) who experienced recurrence, namely being treated again with the same diagnosis within the first year after first being treated. A total of 479 people (97.9%) did not experience pulmonary embolism. The average duration of hospitalization was 13.41 ± 9.89 days. Based on the results of the D-Dimer examination, an average value of 3008.21 ± 1494.59 ng/mL was obtained. Meanwhile, the results of the fibrinogen examination showed an average value of 301.06 ± 58.63 mg/dL. In looking at the comparison of DVT data before and during the COVID-19 pandemic, of the 4 variables looked at, only D-Dimer had a significant difference in the form of an increase in the average value when compared between before the COVID pandemic (2052.34 ± 568.30 ng/mL) and during COVID (3363.89 ± 1573.79 ng/mL) with p value < 0.001. Different results occurred in fibrinogen which did not have a significant difference between before the COVID pandemic (295.66 ± 57.28 mg/dL) compared to during COVID (303.06 ± 59.08 mg/dL) with a p value of 0.223. It was found that COVID-19 patients had higher D-Dimer values (p value <0.001) and significantly higher fibrinogen (p=0.032)."

"Latar Belakang: Di negara maju, angka mortalitas gastroskisis adalah 5-10%, berbeda dengan di negara berkembang. Angka mortalitas gastroskisis mencapai 52% di Brazil, 43% di Afrika Selatan, 35% di Iran, dan 79% di Jamaika. Di RSUPN Cipto Mangunkusumo (RSCM), sampai saat ini belum ada data mengenai angka mortalitas gastrosksis. Angka mortalitas gastroskisis di RSCM perlu diketahui karena karakteristik pasien yang diperkirakan berbeda dengan di negara maju. Tujuan dari penelitian ini adalah untuk mengetahui angka mortalitas gastroskisis di RSCM serta mengidentifikasi faktor risiko yang berpengaruh terhadap mortalitas gastroskisis, antara lain: usia kehamilan, berat badan lahir, jumlah operasi, usia saat operasi pertama kali, serta gastroskisis komplikata.Metode: Metode penelitian ini adalah studi kohort retrospektif dengan total sampling seluruh neonatus yang menjalani operasi penutupan defek di RSCM dari Januari 2015 – September 2020. Analisis bivariat dilakukan menggunakan uji Chi Square atau uji Fisher. Didapatkan 49 subjek neonatus dengan 7 data masuk kategori drop out sehingga 42 subjek diambil untuk dianalisis.Hasil: Angka mortalitas neonatus dengan gastroskisis di RSCM tahun 2015-2020 adalah 69% (29 dari 42 subjek). Pada penelitian ini didapatkan usia saat operasi (<1 hari) berpengaruh menurunkan angka mortalitas gastrosksis (p = 0,005). Usia kehamilan, berat badan lahir, jumlah operasi, dan gastroskisis komplikata didapatkan tidak berpengaruh terhadap angka mortalitas gastroskisis.Kesimpulan: Angka mortalitas gastrokisis di RSCM adalah 69% dan dipengaruhi oleh usia saat operasi.

---

Background: Unlike developing countries, the mortality rate of gastroschizis in developed countries is much lower, accounting at 5-10%. In developing countries, for example, Brazil, the mortality rate can reach up to 52%, 43% in South Africa, 35% in Iran, and 79% in Jamaica. Until recently, there are no data regarding gastrochizis-related mortality rate in Cipto Mangkunkusumo National Referral Hospital, Indonesia. This is important as it reflects patient characteristics that is different with developed countries. The objective of this research is to find out the mortality rate of gastroschizis in Indonesia along with other possible influencing risk factors such as; gestational age, birth weight, number of operations, age at closure, and the presence of complicated gastroschizis.

Methods: A cohort retrospective study with total sampling is used to document all neonates who undergo defect closure surgery from January 2015 to September 2020. Bivariate analysis is done using Chi Square test or Fisher test. A total of 49 neonates were documented, however 7 neonates were excluded due to drop out criteria, resulting in 42 neonates who were included in the analysis.

Results: The mortality rate of gastroschizis in Cipto Mangkunkusumo National Referral Hospital is 69% (29 out of 42 subjects). The age at closure is related to lower mortality rate (p = 0.005), while other factors such as gestational age, birth weight, number of operations, and the presence of complicated gastroschizis has no impact on mortality.

Conclusions: The mortality rate of gastroschizis in Cipto Mangkunkusumo National Referral Hospital is 69% and is influenced by age at closure."